Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
letter
. 2009 Apr 7;32(4):230. doi: 10.1002/clc.20442

A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone

Asterios Karagiannis 1,, Vasilios G Athyros 1, Dimitri P Mikhailidis 2
PMCID: PMC6653455  PMID: 19353701

Full Text

The Full Text of this article is available as a PDF (36.0 KB).

References

  • 1. Struthers A, Krum H, Williams GH. A comparison of the aldosterone‐blocking agents eplerenone and spironolactone. Clin Cardiol. 2008; 31: 153–158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, et al. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opin Pharmacother. 2008; 9: 509–515. [DOI] [PubMed] [Google Scholar]
  • 3. Ménard J. The 45‐year story of the development of an anti‐aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004; 217: 45–52. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES